Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study

• Published in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
• Main Authors: Chamorro-de-Vega, Esther, Calvo, Alberto, Fernández-Pacheco, María, Hernández-Muniesa, Belén, Romero-Jiménez, Rosa, Casado-Gómez, Araceli, Ramírez, Esther, Morell, Alberto, Herrero, Nuria, Úbeda, Bárbara, Ais-Larisgoitia, Arantza, Lobato-Matilla, Elena, Muñoz, Álvaro, Casado, Miguel Ángel, Escudero-Vilaplana, Vicente
• Format: Journal Article
• Language: English
• Published: Spain 23.05.2024
• Subjects: Enfermedades Inflamatorias Inmunes; Servicio de Farmacia; Pharmacy service; Biological therapies; Real-World Evidence; Calidad de vida; Immune-mediated inflammatory diseases; terapias biológicas; Quality of life
• ISSN: 2171-8695

To evaluate health-related quality of life perceived by patients with the most prevalent immune-mediated inflammatory diseases in Spain: inflammatory bowel disease (IBD), psoriasis (Ps), psoriatic arthritis (AP), rheumatoid arthritis (RA), and spondyloarthropathies (SpAs), and to determine the factors that influence patient quality of life. The SACVINFA study (SA=satisfaction, CV=quality of life, IN=immune-mediated, FA=pharmacy) consisted of an observational study conducted in 4 hospitals in the Community of Madrid. A cross-sectional analysis was made for adult patients diagnosed with an immune-mediated inflammatory disease who attended the Pharmacy Service. Quality of life was assessed using the EQ-5D-5L questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and specific questionnaires: SIBDQ-9, DLQI, PsAQoL, QoL-RA, and ASQoL. A total of 578 patients were analysed (inflammatory bowel disease=25.3%; psoriasis=19.7%; spondyloarthropathies=18.7%; rheumatoid arthritis=18.5%; psoriatic arthritis=17.8%). The mean age (standard deviation) was 49.8 (12.3) years and 50.7% were male. The average score (standard deviation) for the global EQ-5D-5L was 0.771 (0.2) and the mean (standard deviation) visual analogue scale score was 71.5 (20.0). Type of immune-mediated inflammatory diseases was associated with differences in quality of life showing psoriasis and inflammatory bowel disease higher values of EQ5D-5L than psoriatic arthritis, rheumatoid arthritis, and spondyloarthropathies, p<.05 in all comparisons. Patients with RA, IBD, and Ps achieved 70% of the maximum score, while patients with PsA and SpAs did not reach 50% of the maximum possible score. Female gender, a state of moderate/severe disease severity, an older age, and a higher number of previous treatments were correlated with worse quality of life. Conversely, persistence to current treatment correlated with better quality of life. Patients with immune-mediated inflammatory diseases have markedly affected quality of life, mainly in the pain/discomfort dimension, especially in those immune-mediated inflammatory diseases with a rheumatological component.